Global Tumor Immunotherapy Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Description

According to our (Global Info Research) latest study, the global Tumor Immunotherapy market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The Global Info Research report includes an overview of the development of the Tumor Immunotherapy industry chain, the market status of Biopharmaceutical Company (Tumor Infiltrating Lymphocyte (TIL) Treatment, Engineered T Cell Receptor (TCR) Therapy), Hospital (Tumor Infiltrating Lymphocyte (TIL) Treatment, Engineered T Cell Receptor (TCR) Therapy), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Tumor Immunotherapy.

Regionally, the report analyzes the Tumor Immunotherapy markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Tumor Immunotherapy market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:
The report presents comprehensive understanding of the Tumor Immunotherapy market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Tumor Immunotherapy industry.

The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Tumor Infiltrating Lymphocyte (TIL) Treatment, Engineered T Cell Receptor (TCR) Therapy).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Tumor Immunotherapy market.

Regional Analysis: The report involves examining the Tumor Immunotherapy market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Tumor Immunotherapy market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Tumor Immunotherapy:
Company Analysis: Report covers individual Tumor Immunotherapy players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Tumor Immunotherapy This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Biopharmaceutical Company, Hospital).

Technology Analysis: Report covers specific technologies relevant to Tumor Immunotherapy. It assesses the current state, advancements, and potential future developments in Tumor Immunotherapy areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Tumor Immunotherapy market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation
Tumor Immunotherapy market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Market segment by Type
    Tumor Infiltrating Lymphocyte (TIL) Treatment
    Engineered T Cell Receptor (TCR) Therapy
    Chimeric Antigen Receptor (CAR) T Cell Therapy
    Natural Killer (NK) Cell Therapy
    Other

Market segment by Application
    Biopharmaceutical Company
    Hospital
    Universities And Other Scientific Research Institutions
    Other

Market segment by players, this report covers
    Roche
    Merck
    Novartis
    Johnson & Johnson
    GlaxoSmithKline
    AbbVie
    ELI Lilly
    Amgen
    AstraZeneca
    Bristol-Mysers Squibb
    Kite Pharma
    Adaptimmune
    Altor Bioscience Corporation
    Cellectis
    Juno Therapeutics
    Takara Bio
    Unum Therapeutics
    Sunway
    Junshi Bio
    Cinda Bio
    BeiGene

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Tumor Immunotherapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Tumor Immunotherapy, with revenue, gross margin and global market share of Tumor Immunotherapy from 2019 to 2024.
Chapter 3, the Tumor Immunotherapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Tumor Immunotherapy market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Tumor Immunotherapy.
Chapter 13, to describe Tumor Immunotherapy research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Tumor Immunotherapy
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Tumor Immunotherapy by Type
        1.3.1 Overview: Global Tumor Immunotherapy Market Size by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Global Tumor Immunotherapy Consumption Value Market Share by Type in 2023
        1.3.3 Tumor Infiltrating Lymphocyte (TIL) Treatment
        1.3.4 Engineered T Cell Receptor (TCR) Therapy
        1.3.5 Chimeric Antigen Receptor (CAR) T Cell Therapy
        1.3.6 Natural Killer (NK) Cell Therapy
        1.3.7 Other
    1.4 Global Tumor Immunotherapy Market by Application
        1.4.1 Overview: Global Tumor Immunotherapy Market Size by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Biopharmaceutical Company
        1.4.3 Hospital
        1.4.4 Universities And Other Scientific Research Institutions
        1.4.5 Other
    1.5 Global Tumor Immunotherapy Market Size & Forecast
    1.6 Global Tumor Immunotherapy Market Size and Forecast by Region
        1.6.1 Global Tumor Immunotherapy Market Size by Region: 2019 VS 2023 VS 2030
        1.6.2 Global Tumor Immunotherapy Market Size by Region, (2019-2030)
        1.6.3 North America Tumor Immunotherapy Market Size and Prospect (2019-2030)
        1.6.4 Europe Tumor Immunotherapy Market Size and Prospect (2019-2030)
        1.6.5 Asia-Pacific Tumor Immunotherapy Market Size and Prospect (2019-2030)
        1.6.6 South America Tumor Immunotherapy Market Size and Prospect (2019-2030)
        1.6.7 Middle East and Africa Tumor Immunotherapy Market Size and Prospect (2019-2030)

2 Company Profiles
    2.1 Roche
        2.1.1 Roche Details
        2.1.2 Roche Major Business
        2.1.3 Roche Tumor Immunotherapy Product and Solutions
        2.1.4 Roche Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Roche Recent Developments and Future Plans
    2.2 Merck
        2.2.1 Merck Details
        2.2.2 Merck Major Business
        2.2.3 Merck Tumor Immunotherapy Product and Solutions
        2.2.4 Merck Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 Merck Recent Developments and Future Plans
    2.3 Novartis
        2.3.1 Novartis Details
        2.3.2 Novartis Major Business
        2.3.3 Novartis Tumor Immunotherapy Product and Solutions
        2.3.4 Novartis Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 Novartis Recent Developments and Future Plans
    2.4 Johnson & Johnson
        2.4.1 Johnson & Johnson Details
        2.4.2 Johnson & Johnson Major Business
        2.4.3 Johnson & Johnson Tumor Immunotherapy Product and Solutions
        2.4.4 Johnson & Johnson Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 Johnson & Johnson Recent Developments and Future Plans
    2.5 GlaxoSmithKline
        2.5.1 GlaxoSmithKline Details
        2.5.2 GlaxoSmithKline Major Business
        2.5.3 GlaxoSmithKline Tumor Immunotherapy Product and Solutions
        2.5.4 GlaxoSmithKline Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 GlaxoSmithKline Recent Developments and Future Plans
    2.6 AbbVie
        2.6.1 AbbVie Details
        2.6.2 AbbVie Major Business
        2.6.3 AbbVie Tumor Immunotherapy Product and Solutions
        2.6.4 AbbVie Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        2.6.5 AbbVie Recent Developments and Future Plans
    2.7 ELI Lilly
        2.7.1 ELI Lilly Details
        2.7.2 ELI Lilly Major Business
        2.7.3 ELI Lilly Tumor Immunotherapy Product and Solutions
        2.7.4 ELI Lilly Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        2.7.5 ELI Lilly Recent Developments and Future Plans
    2.8 Amgen
        2.8.1 Amgen Details
        2.8.2 Amgen Major Business
        2.8.3 Amgen Tumor Immunotherapy Product and Solutions
        2.8.4 Amgen Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        2.8.5 Amgen Recent Developments and Future Plans
    2.9 AstraZeneca
        2.9.1 AstraZeneca Details
        2.9.2 AstraZeneca Major Business
        2.9.3 AstraZeneca Tumor Immunotherapy Product and Solutions
        2.9.4 AstraZeneca Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        2.9.5 AstraZeneca Recent Developments and Future Plans
    2.10 Bristol-Mysers Squibb
        2.10.1 Bristol-Mysers Squibb Details
        2.10.2 Bristol-Mysers Squibb Major Business
        2.10.3 Bristol-Mysers Squibb Tumor Immunotherapy Product and Solutions
        2.10.4 Bristol-Mysers Squibb Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        2.10.5 Bristol-Mysers Squibb Recent Developments and Future Plans
    2.11 Kite Pharma
        2.11.1 Kite Pharma Details
        2.11.2 Kite Pharma Major Business
        2.11.3 Kite Pharma Tumor Immunotherapy Product and Solutions
        2.11.4 Kite Pharma Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        2.11.5 Kite Pharma Recent Developments and Future Plans
    2.12 Adaptimmune
        2.12.1 Adaptimmune Details
        2.12.2 Adaptimmune Major Business
        2.12.3 Adaptimmune Tumor Immunotherapy Product and Solutions
        2.12.4 Adaptimmune Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        2.12.5 Adaptimmune Recent Developments and Future Plans
    2.13 Altor Bioscience Corporation
        2.13.1 Altor Bioscience Corporation Details
        2.13.2 Altor Bioscience Corporation Major Business
        2.13.3 Altor Bioscience Corporation Tumor Immunotherapy Product and Solutions
        2.13.4 Altor Bioscience Corporation Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        2.13.5 Altor Bioscience Corporation Recent Developments and Future Plans
    2.14 Cellectis
        2.14.1 Cellectis Details
        2.14.2 Cellectis Major Business
        2.14.3 Cellectis Tumor Immunotherapy Product and Solutions
        2.14.4 Cellectis Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        2.14.5 Cellectis Recent Developments and Future Plans
    2.15 Juno Therapeutics
        2.15.1 Juno Therapeutics Details
        2.15.2 Juno Therapeutics Major Business
        2.15.3 Juno Therapeutics Tumor Immunotherapy Product and Solutions
        2.15.4 Juno Therapeutics Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        2.15.5 Juno Therapeutics Recent Developments and Future Plans
    2.16 Takara Bio
        2.16.1 Takara Bio Details
        2.16.2 Takara Bio Major Business
        2.16.3 Takara Bio Tumor Immunotherapy Product and Solutions
        2.16.4 Takara Bio Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        2.16.5 Takara Bio Recent Developments and Future Plans
    2.17 Unum Therapeutics
        2.17.1 Unum Therapeutics Details
        2.17.2 Unum Therapeutics Major Business
        2.17.3 Unum Therapeutics Tumor Immunotherapy Product and Solutions
        2.17.4 Unum Therapeutics Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        2.17.5 Unum Therapeutics Recent Developments and Future Plans
    2.18 Sunway
        2.18.1 Sunway Details
        2.18.2 Sunway Major Business
        2.18.3 Sunway Tumor Immunotherapy Product and Solutions
        2.18.4 Sunway Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        2.18.5 Sunway Recent Developments and Future Plans
    2.19 Junshi Bio
        2.19.1 Junshi Bio Details
        2.19.2 Junshi Bio Major Business
        2.19.3 Junshi Bio Tumor Immunotherapy Product and Solutions
        2.19.4 Junshi Bio Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        2.19.5 Junshi Bio Recent Developments and Future Plans
    2.20 Cinda Bio
        2.20.1 Cinda Bio Details
        2.20.2 Cinda Bio Major Business
        2.20.3 Cinda Bio Tumor Immunotherapy Product and Solutions
        2.20.4 Cinda Bio Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        2.20.5 Cinda Bio Recent Developments and Future Plans
    2.21 BeiGene
        2.21.1 BeiGene Details
        2.21.2 BeiGene Major Business
        2.21.3 BeiGene Tumor Immunotherapy Product and Solutions
        2.21.4 BeiGene Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        2.21.5 BeiGene Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Tumor Immunotherapy Revenue and Share by Players (2019-2024)
    3.2 Market Share Analysis (2023)
        3.2.1 Market Share of Tumor Immunotherapy by Company Revenue
        3.2.2 Top 3 Tumor Immunotherapy Players Market Share in 2023
        3.2.3 Top 6 Tumor Immunotherapy Players Market Share in 2023
    3.3 Tumor Immunotherapy Market: Overall Company Footprint Analysis
        3.3.1 Tumor Immunotherapy Market: Region Footprint
        3.3.2 Tumor Immunotherapy Market: Company Product Type Footprint
        3.3.3 Tumor Immunotherapy Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Tumor Immunotherapy Consumption Value and Market Share by Type (2019-2024)
    4.2 Global Tumor Immunotherapy Market Forecast by Type (2025-2030)

5 Market Size Segment by Application
    5.1 Global Tumor Immunotherapy Consumption Value Market Share by Application (2019-2024)
    5.2 Global Tumor Immunotherapy Market Forecast by Application (2025-2030)

6 North America
    6.1 North America Tumor Immunotherapy Consumption Value by Type (2019-2030)
    6.2 North America Tumor Immunotherapy Consumption Value by Application (2019-2030)
    6.3 North America Tumor Immunotherapy Market Size by Country
        6.3.1 North America Tumor Immunotherapy Consumption Value by Country (2019-2030)
        6.3.2 United States Tumor Immunotherapy Market Size and Forecast (2019-2030)
        6.3.3 Canada Tumor Immunotherapy Market Size and Forecast (2019-2030)
        6.3.4 Mexico Tumor Immunotherapy Market Size and Forecast (2019-2030)

7 Europe
    7.1 Europe Tumor Immunotherapy Consumption Value by Type (2019-2030)
    7.2 Europe Tumor Immunotherapy Consumption Value by Application (2019-2030)
    7.3 Europe Tumor Immunotherapy Market Size by Country
        7.3.1 Europe Tumor Immunotherapy Consumption Value by Country (2019-2030)
        7.3.2 Germany Tumor Immunotherapy Market Size and Forecast (2019-2030)
        7.3.3 France Tumor Immunotherapy Market Size and Forecast (2019-2030)
        7.3.4 United Kingdom Tumor Immunotherapy Market Size and Forecast (2019-2030)
        7.3.5 Russia Tumor Immunotherapy Market Size and Forecast (2019-2030)
        7.3.6 Italy Tumor Immunotherapy Market Size and Forecast (2019-2030)

8 Asia-Pacific
    8.1 Asia-Pacific Tumor Immunotherapy Consumption Value by Type (2019-2030)
    8.2 Asia-Pacific Tumor Immunotherapy Consumption Value by Application (2019-2030)
    8.3 Asia-Pacific Tumor Immunotherapy Market Size by Region
        8.3.1 Asia-Pacific Tumor Immunotherapy Consumption Value by Region (2019-2030)
        8.3.2 China Tumor Immunotherapy Market Size and Forecast (2019-2030)
        8.3.3 Japan Tumor Immunotherapy Market Size and Forecast (2019-2030)
        8.3.4 South Korea Tumor Immunotherapy Market Size and Forecast (2019-2030)
        8.3.5 India Tumor Immunotherapy Market Size and Forecast (2019-2030)
        8.3.6 Southeast Asia Tumor Immunotherapy Market Size and Forecast (2019-2030)
        8.3.7 Australia Tumor Immunotherapy Market Size and Forecast (2019-2030)

9 South America
    9.1 South America Tumor Immunotherapy Consumption Value by Type (2019-2030)
    9.2 South America Tumor Immunotherapy Consumption Value by Application (2019-2030)
    9.3 South America Tumor Immunotherapy Market Size by Country
        9.3.1 South America Tumor Immunotherapy Consumption Value by Country (2019-2030)
        9.3.2 Brazil Tumor Immunotherapy Market Size and Forecast (2019-2030)
        9.3.3 Argentina Tumor Immunotherapy Market Size and Forecast (2019-2030)

10 Middle East & Africa
    10.1 Middle East & Africa Tumor Immunotherapy Consumption Value by Type (2019-2030)
    10.2 Middle East & Africa Tumor Immunotherapy Consumption Value by Application (2019-2030)
    10.3 Middle East & Africa Tumor Immunotherapy Market Size by Country
        10.3.1 Middle East & Africa Tumor Immunotherapy Consumption Value by Country (2019-2030)
        10.3.2 Turkey Tumor Immunotherapy Market Size and Forecast (2019-2030)
        10.3.3 Saudi Arabia Tumor Immunotherapy Market Size and Forecast (2019-2030)
        10.3.4 UAE Tumor Immunotherapy Market Size and Forecast (2019-2030)

11 Market Dynamics
    11.1 Tumor Immunotherapy Market Drivers
    11.2 Tumor Immunotherapy Market Restraints
    11.3 Tumor Immunotherapy Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry

12 Industry Chain Analysis
    12.1 Tumor Immunotherapy Industry Chain
    12.2 Tumor Immunotherapy Upstream Analysis
    12.3 Tumor Immunotherapy Midstream Analysis
    12.4 Tumor Immunotherapy Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Tumor Immunotherapy Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Table 2. Global Tumor Immunotherapy Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Table 3. Global Tumor Immunotherapy Consumption Value by Region (2019-2024) & (USD Million)
    Table 4. Global Tumor Immunotherapy Consumption Value by Region (2025-2030) & (USD Million)
    Table 5. Roche Company Information, Head Office, and Major Competitors
    Table 6. Roche Major Business
    Table 7. Roche Tumor Immunotherapy Product and Solutions
    Table 8. Roche Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 9. Roche Recent Developments and Future Plans
    Table 10. Merck Company Information, Head Office, and Major Competitors
    Table 11. Merck Major Business
    Table 12. Merck Tumor Immunotherapy Product and Solutions
    Table 13. Merck Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 14. Merck Recent Developments and Future Plans
    Table 15. Novartis Company Information, Head Office, and Major Competitors
    Table 16. Novartis Major Business
    Table 17. Novartis Tumor Immunotherapy Product and Solutions
    Table 18. Novartis Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 19. Novartis Recent Developments and Future Plans
    Table 20. Johnson & Johnson Company Information, Head Office, and Major Competitors
    Table 21. Johnson & Johnson Major Business
    Table 22. Johnson & Johnson Tumor Immunotherapy Product and Solutions
    Table 23. Johnson & Johnson Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 24. Johnson & Johnson Recent Developments and Future Plans
    Table 25. GlaxoSmithKline Company Information, Head Office, and Major Competitors
    Table 26. GlaxoSmithKline Major Business
    Table 27. GlaxoSmithKline Tumor Immunotherapy Product and Solutions
    Table 28. GlaxoSmithKline Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 29. GlaxoSmithKline Recent Developments and Future Plans
    Table 30. AbbVie Company Information, Head Office, and Major Competitors
    Table 31. AbbVie Major Business
    Table 32. AbbVie Tumor Immunotherapy Product and Solutions
    Table 33. AbbVie Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 34. AbbVie Recent Developments and Future Plans
    Table 35. ELI Lilly Company Information, Head Office, and Major Competitors
    Table 36. ELI Lilly Major Business
    Table 37. ELI Lilly Tumor Immunotherapy Product and Solutions
    Table 38. ELI Lilly Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 39. ELI Lilly Recent Developments and Future Plans
    Table 40. Amgen Company Information, Head Office, and Major Competitors
    Table 41. Amgen Major Business
    Table 42. Amgen Tumor Immunotherapy Product and Solutions
    Table 43. Amgen Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 44. Amgen Recent Developments and Future Plans
    Table 45. AstraZeneca Company Information, Head Office, and Major Competitors
    Table 46. AstraZeneca Major Business
    Table 47. AstraZeneca Tumor Immunotherapy Product and Solutions
    Table 48. AstraZeneca Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 49. AstraZeneca Recent Developments and Future Plans
    Table 50. Bristol-Mysers Squibb Company Information, Head Office, and Major Competitors
    Table 51. Bristol-Mysers Squibb Major Business
    Table 52. Bristol-Mysers Squibb Tumor Immunotherapy Product and Solutions
    Table 53. Bristol-Mysers Squibb Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 54. Bristol-Mysers Squibb Recent Developments and Future Plans
    Table 55. Kite Pharma Company Information, Head Office, and Major Competitors
    Table 56. Kite Pharma Major Business
    Table 57. Kite Pharma Tumor Immunotherapy Product and Solutions
    Table 58. Kite Pharma Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 59. Kite Pharma Recent Developments and Future Plans
    Table 60. Adaptimmune Company Information, Head Office, and Major Competitors
    Table 61. Adaptimmune Major Business
    Table 62. Adaptimmune Tumor Immunotherapy Product and Solutions
    Table 63. Adaptimmune Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 64. Adaptimmune Recent Developments and Future Plans
    Table 65. Altor Bioscience Corporation Company Information, Head Office, and Major Competitors
    Table 66. Altor Bioscience Corporation Major Business
    Table 67. Altor Bioscience Corporation Tumor Immunotherapy Product and Solutions
    Table 68. Altor Bioscience Corporation Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 69. Altor Bioscience Corporation Recent Developments and Future Plans
    Table 70. Cellectis Company Information, Head Office, and Major Competitors
    Table 71. Cellectis Major Business
    Table 72. Cellectis Tumor Immunotherapy Product and Solutions
    Table 73. Cellectis Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 74. Cellectis Recent Developments and Future Plans
    Table 75. Juno Therapeutics Company Information, Head Office, and Major Competitors
    Table 76. Juno Therapeutics Major Business
    Table 77. Juno Therapeutics Tumor Immunotherapy Product and Solutions
    Table 78. Juno Therapeutics Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 79. Juno Therapeutics Recent Developments and Future Plans
    Table 80. Takara Bio Company Information, Head Office, and Major Competitors
    Table 81. Takara Bio Major Business
    Table 82. Takara Bio Tumor Immunotherapy Product and Solutions
    Table 83. Takara Bio Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 84. Takara Bio Recent Developments and Future Plans
    Table 85. Unum Therapeutics Company Information, Head Office, and Major Competitors
    Table 86. Unum Therapeutics Major Business
    Table 87. Unum Therapeutics Tumor Immunotherapy Product and Solutions
    Table 88. Unum Therapeutics Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 89. Unum Therapeutics Recent Developments and Future Plans
    Table 90. Sunway Company Information, Head Office, and Major Competitors
    Table 91. Sunway Major Business
    Table 92. Sunway Tumor Immunotherapy Product and Solutions
    Table 93. Sunway Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 94. Sunway Recent Developments and Future Plans
    Table 95. Junshi Bio Company Information, Head Office, and Major Competitors
    Table 96. Junshi Bio Major Business
    Table 97. Junshi Bio Tumor Immunotherapy Product and Solutions
    Table 98. Junshi Bio Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 99. Junshi Bio Recent Developments and Future Plans
    Table 100. Cinda Bio Company Information, Head Office, and Major Competitors
    Table 101. Cinda Bio Major Business
    Table 102. Cinda Bio Tumor Immunotherapy Product and Solutions
    Table 103. Cinda Bio Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 104. Cinda Bio Recent Developments and Future Plans
    Table 105. BeiGene Company Information, Head Office, and Major Competitors
    Table 106. BeiGene Major Business
    Table 107. BeiGene Tumor Immunotherapy Product and Solutions
    Table 108. BeiGene Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 109. BeiGene Recent Developments and Future Plans
    Table 110. Global Tumor Immunotherapy Revenue (USD Million) by Players (2019-2024)
    Table 111. Global Tumor Immunotherapy Revenue Share by Players (2019-2024)
    Table 112. Breakdown of Tumor Immunotherapy by Company Type (Tier 1, Tier 2, and Tier 3)
    Table 113. Market Position of Players in Tumor Immunotherapy, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
    Table 114. Head Office of Key Tumor Immunotherapy Players
    Table 115. Tumor Immunotherapy Market: Company Product Type Footprint
    Table 116. Tumor Immunotherapy Market: Company Product Application Footprint
    Table 117. Tumor Immunotherapy New Market Entrants and Barriers to Market Entry
    Table 118. Tumor Immunotherapy Mergers, Acquisition, Agreements, and Collaborations
    Table 119. Global Tumor Immunotherapy Consumption Value (USD Million) by Type (2019-2024)
    Table 120. Global Tumor Immunotherapy Consumption Value Share by Type (2019-2024)
    Table 121. Global Tumor Immunotherapy Consumption Value Forecast by Type (2025-2030)
    Table 122. Global Tumor Immunotherapy Consumption Value by Application (2019-2024)
    Table 123. Global Tumor Immunotherapy Consumption Value Forecast by Application (2025-2030)
    Table 124. North America Tumor Immunotherapy Consumption Value by Type (2019-2024) & (USD Million)
    Table 125. North America Tumor Immunotherapy Consumption Value by Type (2025-2030) & (USD Million)
    Table 126. North America Tumor Immunotherapy Consumption Value by Application (2019-2024) & (USD Million)
    Table 127. North America Tumor Immunotherapy Consumption Value by Application (2025-2030) & (USD Million)
    Table 128. North America Tumor Immunotherapy Consumption Value by Country (2019-2024) & (USD Million)
    Table 129. North America Tumor Immunotherapy Consumption Value by Country (2025-2030) & (USD Million)
    Table 130. Europe Tumor Immunotherapy Consumption Value by Type (2019-2024) & (USD Million)
    Table 131. Europe Tumor Immunotherapy Consumption Value by Type (2025-2030) & (USD Million)
    Table 132. Europe Tumor Immunotherapy Consumption Value by Application (2019-2024) & (USD Million)
    Table 133. Europe Tumor Immunotherapy Consumption Value by Application (2025-2030) & (USD Million)
    Table 134. Europe Tumor Immunotherapy Consumption Value by Country (2019-2024) & (USD Million)
    Table 135. Europe Tumor Immunotherapy Consumption Value by Country (2025-2030) & (USD Million)
    Table 136. Asia-Pacific Tumor Immunotherapy Consumption Value by Type (2019-2024) & (USD Million)
    Table 137. Asia-Pacific Tumor Immunotherapy Consumption Value by Type (2025-2030) & (USD Million)
    Table 138. Asia-Pacific Tumor Immunotherapy Consumption Value by Application (2019-2024) & (USD Million)
    Table 139. Asia-Pacific Tumor Immunotherapy Consumption Value by Application (2025-2030) & (USD Million)
    Table 140. Asia-Pacific Tumor Immunotherapy Consumption Value by Region (2019-2024) & (USD Million)
    Table 141. Asia-Pacific Tumor Immunotherapy Consumption Value by Region (2025-2030) & (USD Million)
    Table 142. South America Tumor Immunotherapy Consumption Value by Type (2019-2024) & (USD Million)
    Table 143. South America Tumor Immunotherapy Consumption Value by Type (2025-2030) & (USD Million)
    Table 144. South America Tumor Immunotherapy Consumption Value by Application (2019-2024) & (USD Million)
    Table 145. South America Tumor Immunotherapy Consumption Value by Application (2025-2030) & (USD Million)
    Table 146. South America Tumor Immunotherapy Consumption Value by Country (2019-2024) & (USD Million)
    Table 147. South America Tumor Immunotherapy Consumption Value by Country (2025-2030) & (USD Million)
    Table 148. Middle East & Africa Tumor Immunotherapy Consumption Value by Type (2019-2024) & (USD Million)
    Table 149. Middle East & Africa Tumor Immunotherapy Consumption Value by Type (2025-2030) & (USD Million)
    Table 150. Middle East & Africa Tumor Immunotherapy Consumption Value by Application (2019-2024) & (USD Million)
    Table 151. Middle East & Africa Tumor Immunotherapy Consumption Value by Application (2025-2030) & (USD Million)
    Table 152. Middle East & Africa Tumor Immunotherapy Consumption Value by Country (2019-2024) & (USD Million)
    Table 153. Middle East & Africa Tumor Immunotherapy Consumption Value by Country (2025-2030) & (USD Million)
    Table 154. Tumor Immunotherapy Raw Material
    Table 155. Key Suppliers of Tumor Immunotherapy Raw Materials
List of Figures
    Figure 1. Tumor Immunotherapy Picture
    Figure 2. Global Tumor Immunotherapy Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 3. Global Tumor Immunotherapy Consumption Value Market Share by Type in 2023
    Figure 4. Tumor Infiltrating Lymphocyte (TIL) Treatment
    Figure 5. Engineered T Cell Receptor (TCR) Therapy
    Figure 6. Chimeric Antigen Receptor (CAR) T Cell Therapy
    Figure 7. Natural Killer (NK) Cell Therapy
    Figure 8. Other
    Figure 9. Global Tumor Immunotherapy Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 10. Tumor Immunotherapy Consumption Value Market Share by Application in 2023
    Figure 11. Biopharmaceutical Company Picture
    Figure 12. Hospital Picture
    Figure 13. Universities And Other Scientific Research Institutions Picture
    Figure 14. Other Picture
    Figure 15. Global Tumor Immunotherapy Consumption Value, (USD Million): 2019 & 2023 & 2030
    Figure 16. Global Tumor Immunotherapy Consumption Value and Forecast (2019-2030) & (USD Million)
    Figure 17. Global Market Tumor Immunotherapy Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
    Figure 18. Global Tumor Immunotherapy Consumption Value Market Share by Region (2019-2030)
    Figure 19. Global Tumor Immunotherapy Consumption Value Market Share by Region in 2023
    Figure 20. North America Tumor Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 21. Europe Tumor Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 22. Asia-Pacific Tumor Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 23. South America Tumor Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 24. Middle East and Africa Tumor Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 25. Global Tumor Immunotherapy Revenue Share by Players in 2023
    Figure 26. Tumor Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
    Figure 27. Global Top 3 Players Tumor Immunotherapy Market Share in 2023
    Figure 28. Global Top 6 Players Tumor Immunotherapy Market Share in 2023
    Figure 29. Global Tumor Immunotherapy Consumption Value Share by Type (2019-2024)
    Figure 30. Global Tumor Immunotherapy Market Share Forecast by Type (2025-2030)
    Figure 31. Global Tumor Immunotherapy Consumption Value Share by Application (2019-2024)
    Figure 32. Global Tumor Immunotherapy Market Share Forecast by Application (2025-2030)
    Figure 33. North America Tumor Immunotherapy Consumption Value Market Share by Type (2019-2030)
    Figure 34. North America Tumor Immunotherapy Consumption Value Market Share by Application (2019-2030)
    Figure 35. North America Tumor Immunotherapy Consumption Value Market Share by Country (2019-2030)
    Figure 36. United States Tumor Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 37. Canada Tumor Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 38. Mexico Tumor Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 39. Europe Tumor Immunotherapy Consumption Value Market Share by Type (2019-2030)
    Figure 40. Europe Tumor Immunotherapy Consumption Value Market Share by Application (2019-2030)
    Figure 41. Europe Tumor Immunotherapy Consumption Value Market Share by Country (2019-2030)
    Figure 42. Germany Tumor Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 43. France Tumor Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 44. United Kingdom Tumor Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 45. Russia Tumor Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 46. Italy Tumor Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 47. Asia-Pacific Tumor Immunotherapy Consumption Value Market Share by Type (2019-2030)
    Figure 48. Asia-Pacific Tumor Immunotherapy Consumption Value Market Share by Application (2019-2030)
    Figure 49. Asia-Pacific Tumor Immunotherapy Consumption Value Market Share by Region (2019-2030)
    Figure 50. China Tumor Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 51. Japan Tumor Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 52. South Korea Tumor Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 53. India Tumor Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 54. Southeast Asia Tumor Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 55. Australia Tumor Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 56. South America Tumor Immunotherapy Consumption Value Market Share by Type (2019-2030)
    Figure 57. South America Tumor Immunotherapy Consumption Value Market Share by Application (2019-2030)
    Figure 58. South America Tumor Immunotherapy Consumption Value Market Share by Country (2019-2030)
    Figure 59. Brazil Tumor Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 60. Argentina Tumor Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 61. Middle East and Africa Tumor Immunotherapy Consumption Value Market Share by Type (2019-2030)
    Figure 62. Middle East and Africa Tumor Immunotherapy Consumption Value Market Share by Application (2019-2030)
    Figure 63. Middle East and Africa Tumor Immunotherapy Consumption Value Market Share by Country (2019-2030)
    Figure 64. Turkey Tumor Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 65. Saudi Arabia Tumor Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 66. UAE Tumor Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 67. Tumor Immunotherapy Market Drivers
    Figure 68. Tumor Immunotherapy Market Restraints
    Figure 69. Tumor Immunotherapy Market Trends
    Figure 70. Porters Five Forces Analysis
    Figure 71. Manufacturing Cost Structure Analysis of Tumor Immunotherapy in 2023
    Figure 72. Manufacturing Process Analysis of Tumor Immunotherapy
    Figure 73. Tumor Immunotherapy Industrial Chain
    Figure 74. Methodology
    Figure 75. Research Process and Data Source

Companies Mentioned

Roche
Merck
Novartis
Johnson & Johnson
GlaxoSmithKline
AbbVie
ELI Lilly
Amgen
AstraZeneca
Bristol-Mysers Squibb
Kite Pharma
Adaptimmune
Altor Bioscience Corporation
Cellectis
Juno Therapeutics
Takara Bio
Unum Therapeutics
Sunway
Junshi Bio
Cinda Bio
BeiGene